Greenland Mines (GRML)
Market Price (7/21/2026): $0.23 | Market Cap: $21.6 MilSector: Materials | Industry: Precious Metals & Minerals
Greenland Mines (GRML)
Market Price (7/21/2026): $0.23Market Cap: $21.6 MilSector: MaterialsIndustry: Precious Metals & Minerals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -55% Megatrend and thematic driversMegatrends include Battery Technology & Metals. Themes include Rare Earth Elements. | Weak multi-year price returns2Y Excs Rtn is -121%, 3Y Excs Rtn is -163% | Penny stockMkt Price is 0.2 High stock price volatilityVol 12M is 134% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -55% |
| Megatrend and thematic driversMegatrends include Battery Technology & Metals. Themes include Rare Earth Elements. |
| Weak multi-year price returns2Y Excs Rtn is -121%, 3Y Excs Rtn is -163% |
| Penny stockMkt Price is 0.2 |
| High stock price volatilityVol 12M is 134% |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/20/2026
Greenland Mines (GRML) stock has lost about 45% since 3/31/2026 because of the following key factors:
1. Persistent Net Losses and Negative Cash Flow Fueled Investor Concerns. Greenland Mines reported a net loss of -$13.9 million for fiscal Q1 2026, which ended on March 31, 2026, with these results announced on May 20, 2026. This contributed to a trailing twelve months net income of -$22.17 million as of March 31, 2026, and the company also experienced a negative operating cash flow of -$5.9 million. These ongoing financial losses and cash burn significantly eroded investor confidence during the period.
2. Shareholder Approval for Potential Dilution and Reverse Stock Splits Signaled Financial Distress. During the period, Greenland Mines sought approvals for a Series C, warrant, and equity plan, indicating potential further dilution for existing shareholders. Furthermore, shareholders approved a proposal allowing the board to execute reverse stock splits with ratios ranging from 1-for-2 to 1-for-50, valid through March 2027. This approval is often interpreted as a sign of financial weakness and an attempt to maintain listing requirements, further contributing to the negative sentiment.
Show more
Greenland Mines (GRML) stock has lost about 45% since 3/31/2026 because of the following key factors:
1. Persistent Net Losses and Negative Cash Flow Fueled Investor Concerns. Greenland Mines reported a net loss of -$13.9 million for fiscal Q1 2026, which ended on March 31, 2026, with these results announced on May 20, 2026. This contributed to a trailing twelve months net income of -$22.17 million as of March 31, 2026, and the company also experienced a negative operating cash flow of -$5.9 million. These ongoing financial losses and cash burn significantly eroded investor confidence during the period.
2. Shareholder Approval for Potential Dilution and Reverse Stock Splits Signaled Financial Distress. During the period, Greenland Mines sought approvals for a Series C, warrant, and equity plan, indicating potential further dilution for existing shareholders. Furthermore, shareholders approved a proposal allowing the board to execute reverse stock splits with ratios ranging from 1-for-2 to 1-for-50, valid through March 2027. This approval is often interpreted as a sign of financial weakness and an attempt to maintain listing requirements, further contributing to the negative sentiment.
Show more
Updated on 7/20/2026
Greenland Mines (GRML) stock has lost about 45% since 3/31/2026 because of the following key factors:
1. Persistent Net Losses and Negative Cash Flow Fueled Investor Concerns. Greenland Mines reported a net loss of -$13.9 million for fiscal Q1 2026, which ended on March 31, 2026, with these results announced on May 20, 2026. This contributed to a trailing twelve months net income of -$22.17 million as of March 31, 2026, and the company also experienced a negative operating cash flow of -$5.9 million. These ongoing financial losses and cash burn significantly eroded investor confidence during the period.
2. Shareholder Approval for Potential Dilution and Reverse Stock Splits Signaled Financial Distress. During the period, Greenland Mines sought approvals for a Series C, warrant, and equity plan, indicating potential further dilution for existing shareholders. Furthermore, shareholders approved a proposal allowing the board to execute reverse stock splits with ratios ranging from 1-for-2 to 1-for-50, valid through March 2027. This approval is often interpreted as a sign of financial weakness and an attempt to maintain listing requirements, further contributing to the negative sentiment.
3. Positive Project Updates Failed to Offset Overarching Financial Concerns. Despite positive company-specific news, such as a July 15, 2026, announcement of a 31% increase in indicated contained palladium equivalent metal and a 36% increase in indicated grade at its Skaergaard project, these developments did not halt the stock's decline. The stock continued its downward trend, suggesting that the market remained focused on the company's persistent financial losses and the potential for future dilution rather than the long-term potential of its projects.
Show less
Greenland Mines (GRML) stock has lost about 45% since 3/31/2026 because of the following key factors:
1. Persistent Net Losses and Negative Cash Flow Fueled Investor Concerns. Greenland Mines reported a net loss of -$13.9 million for fiscal Q1 2026, which ended on March 31, 2026, with these results announced on May 20, 2026. This contributed to a trailing twelve months net income of -$22.17 million as of March 31, 2026, and the company also experienced a negative operating cash flow of -$5.9 million. These ongoing financial losses and cash burn significantly eroded investor confidence during the period.
2. Shareholder Approval for Potential Dilution and Reverse Stock Splits Signaled Financial Distress. During the period, Greenland Mines sought approvals for a Series C, warrant, and equity plan, indicating potential further dilution for existing shareholders. Furthermore, shareholders approved a proposal allowing the board to execute reverse stock splits with ratios ranging from 1-for-2 to 1-for-50, valid through March 2027. This approval is often interpreted as a sign of financial weakness and an attempt to maintain listing requirements, further contributing to the negative sentiment.
3. Positive Project Updates Failed to Offset Overarching Financial Concerns. Despite positive company-specific news, such as a July 15, 2026, announcement of a 31% increase in indicated contained palladium equivalent metal and a 36% increase in indicated grade at its Skaergaard project, these developments did not halt the stock's decline. The stock continued its downward trend, suggesting that the market remained focused on the company's persistent financial losses and the potential for future dilution rather than the long-term potential of its projects.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
3/31/2026 to 7/20/2026| Return | Correlation | |
|---|---|---|
| GRML | -43.5% | |
| Market (SPY) | 14.1% | 26.3% |
| Sector (XLB) | 0.1% | 15.6% |
Fundamental Drivers
nullnull
Market Drivers
12/31/2025 to 7/20/2026| Return | Correlation | |
|---|---|---|
| GRML | -35.4% | |
| Market (SPY) | 9.1% | 17.1% |
| Sector (XLB) | 10.8% | 11.7% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2025 to 7/20/2026| Return | Correlation | |
|---|---|---|
| GRML | -83.5% | |
| Market (SPY) | 21.1% | 21.6% |
| Sector (XLB) | 15.6% | 14.8% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/20/2026| Return | Correlation | |
|---|---|---|
| GRML | -98.2% | |
| Market (SPY) | 73.3% | 4.7% |
| Sector (XLB) | 27.4% | 5.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GRML Return | - | 2% | 6% | -95% | -40% | -28% | -98% |
| Peers Return | -4% | -14% | -15% | -15% | 8063% | -9% | 4310% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| GRML Win Rate | - | 44% | 83% | 33% | 25% | 29% | |
| Peers Win Rate | 29% | 42% | 31% | 35% | 65% | 37% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| GRML Max Drawdown | - | - | -2% | -98% | -86% | -73% | |
| Peers Max Drawdown | -37% | -42% | -35% | -33% | -53% | -50% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRML, PLG, MP, USAR, NEM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/20/2026 (YTD)
How Low Can It Go
| Event | GRML | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -65.9% | -18.8% |
| % Gain to Breakeven | 193.6% | 23.1% |
| Time to Breakeven | 27 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -44.1% | -7.8% |
| % Gain to Breakeven | 79.0% | 8.5% |
| Time to Breakeven | 299 days | 18 days |
In The Past
Greenland Mines's stock fell -65.9% during the 2025 US Tariff Shock. Such a loss loss requires a 193.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | GRML | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -65.9% | -18.8% |
| % Gain to Breakeven | 193.6% | 23.1% |
| Time to Breakeven | 27 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -44.1% | -7.8% |
| % Gain to Breakeven | 79.0% | 8.5% |
| Time to Breakeven | 299 days | 18 days |
In The Past
Greenland Mines's stock fell -65.9% during the 2025 US Tariff Shock. Such a loss loss requires a 193.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Greenland Mines (GRML)
Greenland Mines (GRML), operating as Klotho Neurosciences, Inc., is a biopharmaceutical company dedicated to developing innovative therapies and specialty diagnostics. Its core focus is on addressing neurological and age-related disorders, with a mission to mitigate severe conditions such as dementia symptoms, Alzheimer's disease, and various neuromuscular diseases.
The company's product portfolio is diverse, featuring advanced cell and gene therapies aimed at enhancing longevity and reducing age-related pathologies. Additionally, GRML develops biologics and biosimilars primarily for the treatment of cancer, alongside research into melanocortin receptors. A significant aspect of its research and development involves a strategic partnership with Japan's Okinawa Research Center, specifically for Klotho gene therapy focused on extending longevity and combating age-related illnesses.
Greenland Mines (GRML) primarily serves patient populations affected by neurological and age-related disorders, as well as individuals undergoing cancer treatment. Its efforts position the company within critical healthcare markets focused on improving quality of life and extending healthy lifespans through cutting-edge biomedical solutions.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Greenland Mines Ltd. (GRML) operates in two primary sectors: mineral exploration and development, and biotechnology. The company's main products and services include precious metals (palladium, gold, and platinum) and rare earth elements (neodymium and praseodymium) from its mining operations, as well as essential medicines for chronic diseases, including a generic drug portfolio, biosimilar biologics for cancer treatment, and gene therapies for neurodegenerative disorders, which involve the Klotho protein.
The addressable markets for Greenland Mines' products and services are substantial:
- Precious Metals (Palladium, Gold, Platinum): The company's Skaergaard Project in Southeast Greenland holds significant resources, with an estimated gross undiscounted in-situ metal value of approximately $68 billion based on February 2026 metal prices. While this represents resource value rather than an annual market, it indicates the scale of the underlying commodity markets. Globally, the precious metals market is extensive.
- Rare Earth Elements (Neodymium, Praseodymium): Greenland Mines is expanding its critical minerals platform to include rare earths. The global rare earth elements market was valued at $10.19 billion in 2023 and is projected to reach $20.50 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.20%. This market includes vital components for electric vehicle motors, wind turbines, and advanced electronics.
- Cell and Gene Therapies for Neurodegenerative Disorders: Greenland Mines is involved in the development of gene therapies using the Klotho protein for neurodegenerative diseases like ALS. The global cell and gene therapy market was valued at $18.61 billion in 2023 and is expected to grow to $203.26 billion by 2033, demonstrating a CAGR of 26.6%. Specifically, the global market for Alzheimer's disease therapeutics was valued at $6.7 billion in 2023 and is projected to reach $17.8 billion by 2033, with a CAGR of 10.3%. The anti-aging products market, related to Klotho's longevity aspects, was valued at $14.05 billion in the U.S. in 2024 and is forecasted to reach $27.44 billion by 2033, with a CAGR of 8.0%. Globally, the anti-aging market is expected to surpass $421.4 billion in revenue by 2030, with an 8.1% CAGR.
- Biosimilars for Cancer Treatment: The company's biotechnology segment includes a biosimilar biologics platform for treating cancer. The global oncology biosimilars market size was valued at $4.49 billion in 2023 and is projected to grow to $28.31 billion by 2033, exhibiting a CAGR of 20.32%.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.72 |
| Mkt Cap | 3.0 |
| Rev LTM | 131 |
| Op Inc LTM | -46 |
| FCF LTM | -69 |
| FCF 3Y Avg | -7 |
| CFO LTM | -31 |
| CFO 3Y Avg | -4 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 22.3% |
| Rev Chg 3Y Avg | 9.6% |
| Rev Chg Q | 47.5% |
| QoQ Delta Rev Chg LTM | 13.3% |
| Op Inc Chg LTM | 1.4% |
| Op Inc Chg 3Y Avg | 3.5% |
| Op Mgn LTM | -50.9% |
| Op Mgn 3Y Avg | -10.2% |
| QoQ Delta Op Mgn LTM | 13.7% |
| CFO/Rev LTM | -37.2% |
| CFO/Rev 3Y Avg | 8.8% |
| FCF/Rev LTM | -123.4% |
| FCF/Rev 3Y Avg | -46.2% |
Price Behavior
Price Behavior
| Market Price | $0.19 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 04/29/2022 | |
| Distance from 52W High | -86.2% | |
| 50 Days | 200 Days | |
| DMA Price | $0.31 | $0.39 |
| DMA Trend | down | down |
| Distance from DMA | -38.9% | -51.8% |
| 3M | 1YR | |
| Volatility | 124.1% | 134.6% |
| Downside Capture | 470.30 | 421.94 |
| Upside Capture | 28.53 | 108.13 |
| Correlation (SPY) | 20.8% | 22.4% |
GRML Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.89 | 1.06 | 3.20 | 1.99 | 2.50 | 1.45 |
| Up Beta | 2.45 | 2.39 | 5.24 | 4.27 | 4.14 | -1.29 |
| Down Beta | 3.74 | 1.40 | 0.52 | -0.02 | 0.37 | 1.17 |
| Up Capture | -199% | -133% | 194% | 181% | 258% | 220% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 9 | 17 | 27 | 55 | 100 | 265 |
| Down Capture | 128% | 252% | 340% | 193% | 192% | 113% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 12 | 24 | 36 | 70 | 151 | 364 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRML | |
|---|---|---|---|---|
| GRML | -86.4% | 134.3% | -0.89 | - |
| Sector ETF (XLB) | 12.8% | 17.6% | 0.53 | 16.0% |
| Equity (SPY) | 19.2% | 12.6% | 1.12 | 22.7% |
| Gold (GLD) | 19.6% | 28.0% | 0.63 | 26.8% |
| Commodities (DBC) | 29.7% | 19.0% | 1.24 | 0.6% |
| Real Estate (VNQ) | 15.2% | 14.0% | 0.78 | 9.4% |
| Bitcoin (BTCUSD) | -46.6% | 42.9% | -1.34 | 15.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRML | |
|---|---|---|---|---|
| GRML | -54.7% | 501.0% | 0.38 | - |
| Sector ETF (XLB) | 5.7% | 19.0% | 0.20 | 4.7% |
| Equity (SPY) | 12.6% | 17.1% | 0.57 | 4.3% |
| Gold (GLD) | 16.8% | 18.4% | 0.74 | 3.5% |
| Commodities (DBC) | 8.8% | 19.5% | 0.34 | 1.1% |
| Real Estate (VNQ) | 2.6% | 18.9% | 0.04 | 1.9% |
| Bitcoin (BTCUSD) | 14.0% | 53.5% | 0.44 | 8.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRML | |
|---|---|---|---|---|
| GRML | -32.6% | 501.0% | 0.38 | - |
| Sector ETF (XLB) | 10.0% | 20.6% | 0.43 | 4.7% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 4.3% |
| Gold (GLD) | 10.9% | 16.1% | 0.55 | 3.5% |
| Commodities (DBC) | 7.0% | 17.9% | 0.31 | 1.1% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 1.9% |
| Bitcoin (BTCUSD) | 57.9% | 66.2% | 0.98 | 8.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/20/2026 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/20/2026 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/20/2026